U.S. Animal Health Market Expected to Reach $47.65B by 2034

The U.S. animal health market is experiencing robust growth, transitioning from an impressive $20.92 billion in 2025 to a projected $47.65 billion by 2034. This nearly double increase is driven by several pivotal factors, including rising pet ownership, increasing disease challenges in livestock, and advancements in veterinary diagnostics and biological products. Pet humanization, where pets are treated more like family members rather than just animals, is contributing substantially to this growth, with pet owners willing to spend more on healthcare for their companions. In tandem, the need for effective management of livestock diseases is elevating demand for veterinary pharmaceuticals, fostering a fertile environment for government procurement opportunities.

The rising demand for vaccines, antibiotics, and biosecurity products to combat diseases such as bovine respiratory disease and avian influenza signifies not just an industry pivot but also invites government agencies to reassess their acquisition strategies. Agencies focusing on animal health and agricultural biosecurity will likely update their procurement processes to integrate new technologies and products that align with the goal of ensuring animal wellbeing and food safety standards. The integration of advanced diagnostic technologies and novel vaccine platforms into procurement will be paramount in addressing these rising health challenges facing both companion animals and commercial livestock.

As the market is projected to grow at a compound annual growth rate (CAGR) of 9.58% during 2026-2034, companies involved in animal health pharmaceuticals and diagnostics are encouraged to position themselves strategically to leverage government contracts. A focus on regional government procurement, particularly in major hub areas such as Parsippany, New Jersey, could enhance competitive advantages and improve engagement with federal contracts.

The implications of this market expansion are far-reaching. Procurement teams within relevant federal agencies will likely find increased opportunities to align their contracts with emerging trends in animal health, particularly regarding veterinary products and services aimed at livestock disease management and pet health initiatives. This aligns not only with public health goals but also with agricultural policies focused on sustainable animal production. As the landscape evolves, stakeholders must remain agile to adapt to the shifting demands of the animal health sector.

Ultimately, the burgeoning U.S. animal health market serves as both a challenge and an opportunity. Stakeholders are advised to maintain awareness of changing dynamics within the marketplace, as these factors will shape procurement strategies moving forward. Establishing partnerships with leading industry vendors, such as Zoetis Services LLC, Merck & Co. Inc., Elanco, and Boehringer Ingelheim International GmbH, offers potential procurement pathways critical for supporting veterinary healthcare goals in the United States.

In summary, the U.S. animal health market's expected growth signifies a clear call to action for government agencies and contractors alike to bolster their engagements with veterinary products and support systems that emphasize both animal welfare and agricultural integrity.